AstraZeneca/Pozen Target 2009 For Arthritis Combination Filing
Companies will initiate a Phase III clinical trial for PN400, a combination of naproxen and the esomeprazole.
Companies will initiate a Phase III clinical trial for PN400, a combination of naproxen and the esomeprazole.